These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32667984)

  • 1. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
    Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
    Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
    Yao C; Guo H; Li Q; Zhang X; Shang Y; Li T; Wang Y; Xue Z; Wang L; Li L; Pang Y
    Antimicrob Resist Infect Control; 2021 Aug; 10(1):126. PubMed ID: 34446095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan.
    Saeed DK; Shakoor S; Razzak SA; Hasan Z; Sabzwari SF; Azizullah Z; Kanji A; Nasir A; Shafiq S; Ghanchi NK; Hasan R
    BMC Microbiol; 2022 Feb; 22(1):62. PubMed ID: 35209842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.
    Ahmad Khosravi N; Sirous M; Khosravi AD; Saki M
    J Clin Lab Anal; 2024 Aug; 38(15-16):e25091. PubMed ID: 39431709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.
    Ismail NA; Omar SV; Joseph L; Govender N; Blows L; Ismail F; Koornhof H; Dreyer AW; Kaniga K; Ndjeka N
    EBioMedicine; 2018 Feb; 28():136-142. PubMed ID: 29337135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis.
    Brown TS; Tang L; Omar SV; Joseph L; Meintjes G; Maartens G; Wasserman S; Shah NS; Farhat MR; Gandhi NR; Ismail N; Brust JCM; Mathema B
    Clin Infect Dis; 2024 Feb; 78(2):269-276. PubMed ID: 37874928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data.
    Li S; Tan Y; Deng Y; Bai G; Huang M; Shang Y; Wang Y; Xue Z; Zhang X; Wang W; Pan J; Pang Y
    J Infect Public Health; 2024 Jan; 17(1):137-142. PubMed ID: 38000314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
    Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
    Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey.
    Wang G; Jiang G; Jing W; Zong Z; Yu X; Chen S; Li W; Huang H
    J Infect; 2021 Mar; 82(3):371-377. PubMed ID: 33556430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis.
    Xu J; Li D; Shi J; Wang B; Ge F; Guo Z; Mu X; Nuermberger E; Lu Y
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0153222. PubMed ID: 37255473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
    Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
    J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678.
    Snobre J; Villellas MC; Coeck N; Mulders W; Tzfadia O; de Jong BC; Andries K; Rigouts L
    Sci Rep; 2023 Jun; 13(1):10444. PubMed ID: 37369740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
    Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A
    BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of bedaquiline resistance and genetic mutations in multi-drug resistant Mycobacterium tuberculosis clinical isolates in Chongqing, China.
    Hu Y; Fan J; Zhu D; Liu W; Li F; Li T; Zheng H
    Ann Clin Microbiol Antimicrob; 2023 Feb; 22(1):19. PubMed ID: 36855179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran.
    Madadi-Goli N; Ahmadi K; Kamakoli MK; Azizi M; Khanipour S; Dizaji SP; Nasehi M; Siadat SD; Fateh A; Vaziri F
    Ann Clin Microbiol Antimicrob; 2024 Apr; 23(1):36. PubMed ID: 38664815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
    Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.